Webinar for Sporadic MTC Patients

AMEND is delighted to be hosting a free, live webinar for the sporadic medullary thyroid cancer (MTC) community on Wednesday 18th June from 19:00-20:30.  Our expert speakers are Consultant Endocrinologist, Dr Daniel Morganstein, and Consultant Clinical Oncologist, Dr Kate Newbold, both from the Royal Marsden Hospital in London.   We hope you can join us.

Click here to register

Selpercatinib – Can you Help?

AMEND is preparing a patient group submission for the Scottish Medicine's Consortium for the assessment of selpercatinib for use in metastatic MTC with the hope of getting it approved. Can you help us by sending us your input?

Click here for more information

Annual Patient Information Day Booking Open

The 2025 AMEND Annual Patient Information Day will be held on Saturday 31st May in central London.  Disease-specific Q&A sessions with medical experts will be held in the morning and followed by other useful and topical sessions throughout the day.  This event is FREE.

Click here for more information and to book

2024 Annual Patient Information Day

AMEND's 2024 Annual Patient Information Day will be held on Saturday 1st June, in central Birmingham. This event is open to anyone affected by MEN or PPGL syndromes, as well as for those affected by ACC and MTC.  Come along and benefit from a 2-hour Q&A session with an expert in your disease, as well as plenty of other relevant sessions.  There is a separate stream for young adults from 12 years of age. Tickets are available on a donation basis (minimum £1 per ticket).

Click here for more information and to book

NETS in RETS

November 10th each year is NET Cancer Day, initiated by the International Neuroendocrine Cancer Alliance, of which AMEND is a member representing genetic neuroendocrine tumour syndromes.  To better explain the link between NETs and RETS (rare endocrine tumours and syndromes), join us for our webinar, NETs in RETS, with Professor Karim Meeran on Thursday 9th November from 18:00-19:00.

Click here for more information

AMEND Annual Patient Information Day Success

The sun was shining on Saturday 20^th May in London for our Annual Patient Information Day, and our venue beside the Regent’s Canal was the perfect place to receive all the members of our rare endocrine diseases communities who had booked to attend.

Click here to read more

2022 Annual Patient Information Day

Our 2022 Annual Patient Information Day for anyone affected by MEN and PPGL syndromes, ACC and MTC, will be held at the Holiday Inn, 25 Aytoun Street, Manchester M1 3AE, on Saturday 7th May.  We would love to see as many of our members and friends there as possible.  For more information on the programme and local hotels, as well as to book your spaces, please visit our dedicated webpage.

Click here for more information

Community Advisory Groups Still Recruiting

We are still seeking enthusiastic, motivated and knowledgeable people to volunteer as members of our Community Advisory Groups (CAGs) for MEN2, MEN3 and PPGL syndromes.  Our CAGs are already established for MEN1, ACC and MTC and some have already been involved in research projects and other activities.

Click here for more information

Selpercatinib Approved for Metastatic MTC

In September, selpercatinib (also known as LOXO) was approved in England (Cancer Drugs Fund) and Scotland (Interim Basis) for use in metastatic RET-mutation medullary thyroid cancer (MTC) as well as other RET-fusion positive thyroid cancers.

Get Ready for Thyroid Cancer Awareness Month!

September is Thyroid Cancer Awareness Month, and we'll be raising awareness of medullary thyroid cancer.  Here's how you can help.....!

Click here for more information